CD3 Antibody (CA17.2A12)
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-49891
Conjugate
Catalog #
Key Product Details
Species Reactivity
Validated:
Canine
Cited:
Canine
Applications
Validated:
Flow Cytometry, Immunofluorescence, Immunohistochemistry, Immunohistochemistry-Frozen, Immunoprecipitation
Cited:
Flow Cytometry
Label
Unconjugated
Antibody Source
Monoclonal Mouse IgG1 Clone # CA17.2A12
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Specifications
Immunogen
Affinity enriched TCR/CD3 membrane proteins isolated from thymocytes and the T cell line CLGL-90
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Scientific Data Images for CD3 Antibody (CA17.2A12)
Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891]
Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A. Purified Rat anti Canine CD90 detected with Goat anti Rat IgG2a DyLight 649 and Mouse IgG1 FITC isotype control. Figure B. Purified Rat anti Canine CD90 detected with Goat anti Rat IgG2a PE and Mouse anti Canine CD3 FITC.Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891]
Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A: APC conjugated rat anti-Canine CD4 and FITC conjugated mouse IgG1 isotype control. Figure B: APC conjugated rat anti-Canine CD4 and FITC conjugated mouse anti-Canine CD3.Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891]
Flow Cytometry: CD3 Antibody (CA17.2A12) [NBP2-49891] - Figure A: RPE conjugated Rat anti-Dog CD4 and Mouse IgG1 isotype control labeled with Goat anti-Mouse FITC. Figure B: RPE conjugated Rat anti-Dog CD4 and Mouse anti-Dog CD3 labeled with Goat anti Mouse DyLight FITC.Applications for CD3 Antibody (CA17.2A12)
Application
Recommended Usage
Flow Cytometry
1:25 - 1:50
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein G purified
Formulation
PBS
Preservative
0.09% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
Background: CD3
CD3 proteins are expressed on the surface of thymocytes during thymocyte development, proliferation, and maturation to T-cells (4, 6, 7). During T-cell development CD4-CD8- double negative (DN) cells differentiate to CD4+CD8+ double positive (DP) cells before progressing to single positive (SP) CD4+ helper T-cells or CD8+ cytotoxic T-cells (4, 6, 7). As CD3 plays an important role in thymocyte development, it is understandable that CD3 defects and mutations in CD3 protein chains cause severe combined immunodeficiencies (SCIDs) (8). Additionally, a subset of CD3+ T-cells that co-express CD20 are described in a variety of diseases including rheumatoid arthritis, multiple sclerosis, CD20+ T-cell leukemia/lymphoma, and HIV (9). Clinical trials and animal models have shown that anti-CD3 monoclonal antibodies are a promising treatment modality for inflammatory disorders and autoimmune diseases, such as type I diabetes (10).
References
1. Chetty, R., & Gatter, K. (1994). CD3: structure, function, and role of immunostaining in clinical practice. The Journal of pathology. https://doi.org/10.1002/path.1711730404
2. Mariuzza, R. A., Agnihotri, P., & Orban, J. (2020). The structural basis of T-cell receptor (TCR) activation: An enduring enigma. The Journal of biological chemistry. https://doi.org/10.1074/jbc.REV119.009411
3. Kuhns, M. S., Davis, M. M., & Garcia, K. C. (2006). Deconstructing the form and function of the TCR/CD3 complex. Immunity. https://doi.org/10.1016/j.immuni.2006.01.006
4. Clevers, H., Alarcon, B., Wileman, T., & Terhorst, C. (1988). The T cell receptor/CD3 complex: a dynamic protein ensemble. Annual review of immunology. https://doi.org/10.1146/annurev.iy.06.040188.003213
5. Uniprot: CD3-delta (P04234), CD3-epsilon (P07766), CD3-gamma (P09693), CD3-zeta (P20963)
6. D'Acquisto, F., & Crompton, T. (2011). CD3+CD4-CD8- (double negative) T cells: saviours or villains of the immune response?. Biochemical pharmacology. https://doi.org/10.1016/j.bcp.2011.05.019
7. Dave V. P. (2009). Hierarchical role of CD3 chains in thymocyte development. Immunological reviews. https://doi.org/10.1111/j.1600-065X.2009.00835.x
8. Fischer, A., de Saint Basile, G., & Le Deist, F. (2005). CD3 deficiencies. Current opinion in allergy and clinical immunology. https://doi.org/10.1097/01.all.0000191886.12645.79
9. Chen, Q., Yuan, S., Sun, H., & Peng, L. (2019). CD3+CD20+ T cells and their roles in human diseases. Human immunology. https://doi.org/10.1016/j.humimm.2019.01.001
10. Kuhn, C., & Weiner, H. L. (2016). Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. Immunotherapy. https://doi.org/10.2217/imt-2016-0049
Alternate Names
CD_antigen: CD3e, CD3 antigen, delta subunit, CD3d antigen, CD3d antigen, delta polypeptide (TiT3 complex), CD3d molecule, delta (CD3-TCR complex), CD3-DELTA, CD3e, CD3e antigen, CD3e antigen, epsilon polypeptide (TiT3 complex), CD3e molecule, epsilon (CD3-TCR complex), CD3-epsilon, CD3G, CD3g antigen, CD3g antigen, gamma polypeptide (TiT3 complex), CD3g molecule, epsilon (CD3-TCR complex), CD3g molecule, gamma (CD3-TCR complex), CD3-GAMMA, FLJ17620, FLJ17664, FLJ18683, FLJ79544, FLJ94613, IMD18, MGC138597, T3DOKT3, delta chain, T3E, T-cell antigen receptor complex, epsilon subunit of T3, T-cell receptor T3 delta chain, T-cell surface antigen T3/Leu-4 epsilon chain, T-cell surface glycoprotein CD3 delta chain, T-cell surface glycoprotein CD3 epsilon chain, TCRE
Gene Symbol
CD3E
UniProt
Additional CD3 Products
Product Documents for CD3 Antibody (CA17.2A12)
Product Specific Notices for CD3 Antibody (CA17.2A12)
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...